663 related articles for article (PubMed ID: 15491240)
1. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Maina G; Albert U; Salvi V; Bogetto F
J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
[TBL] [Abstract][Full Text] [Related]
2. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
7. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
[TBL] [Abstract][Full Text] [Related]
8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
9. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Carpenter LL; McDougle CJ; Epperson CN; Price LH
Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
[TBL] [Abstract][Full Text] [Related]
10. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Todorov C; Freeston MH; Borgeat F
Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
[TBL] [Abstract][Full Text] [Related]
11. Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.
Levy DM; Arush OB; Carmi L; Wetzler AJ; Zohar J
Compr Psychiatry; 2024 Aug; 133():152486. PubMed ID: 38703743
[TBL] [Abstract][Full Text] [Related]
12. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
Flament MF; Bisserbe JC
J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
[TBL] [Abstract][Full Text] [Related]
14. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
[TBL] [Abstract][Full Text] [Related]
18. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Bailly D
Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of drug response in obsessive-compulsive disorder.
Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L
J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
